| Prev Close | 36.86 |
| Day Low/High | 36.53 / 38.15 |
| 52 Wk Low/High | 23.55 / 40.00 |
ANI Pharmaceuticals, Inc. (ANIP)
38.08
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 12.76B |
| Market Cap | 470.42M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
The Bulls Are Back in Town: 20 Stocks I'm Trading
There is so much going on right now that it is overwhelming.
Profit-Taking Is Kicking In: Here Are Some Names on My Shopping List
Study those charts and be ready to act as things develop.
Here's What I Usually Do When We See These Sort of Selloffs in 2020
Market is down 2% across the board in late morning trading as Consumer Sentiment rises less than expected. Hardly surprising given the non stop litany of recent negative headlines on the Covid-19 front as well as the various protests, some violent, ...
Check Out These 2 Undervalued Drugmakers
I plan to add some additional exposure to each on the next 'hiccup' in the market using my usual covered call strategy.
Even Wall Street Experts Had a Tough Year in 2018
Barron's big-name money managers did not pick many winners for the year.
Even the Experts Had a Tough Year in 2018
Barron's big-name money managers did not pick many winners for the year.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Small-Caps Offer Port in Stormy Trade Seas
Small-caps also should benefit from reduced corporate income taxes and strong U.S. economic growth.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
3 Promising Biotech Stocks to Buy on Dips
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Three Biotech Opportunities
Celgene, ANI and T2 are seeing attractive entry points.
3 Small-Caps on My Growth Stock Radar
LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.
2 Small Biopharma Stocks on the Move
The oversold biotech sector is recovering.
Cashing In on the Biotech Bear Market
My 4-Tier approach to deploying new capital in the sector.
Stocks Slightly Lower Amid Yellen's Rate-Hike Hints
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...
Thank God It's Friday!
Good morning! Bret Jensen here. I'm happy to be filling in for Doug Kass during this last trading day of October. It's been a good month for investors after a very bumpy August and September. All the major indices are up nicely for the month, despit...
6 Biotechs I Like for Earnings Season
These stocks should all show solid third-quarter results.
How to Build a Good Foundation in Biotechs
A so-called "pyramid strategy" can help you enter the depressed sector.
Horizon and ANI Appeal in Pharma Selloff
Some smaller biotechs offer good value at current levels.
Biotech Investors: Ignore Hillary's Election-Inspired Silliness
Does anyone think efforts to inject more government into the private health care market will go anywhere?
Biotech, Hillary and Election Silliness
Does anyone think efforts to inject more government into the private health care market will go anywhere?
Celgene on My Shopping List for a Pullback
I have about 25% in cash; if the market falls 5-10%, I'm in.
Why You Should Adopt Little Orphan ANI
The sun could come out tomorrow for this small, depressed biotech.
Failed Greece Negotiations Hit Futures; Dollar Worries Persist
But investors are likely to be wary ahead of the Fed meeting.
Put Health Care Stocks on Shopping List
Have it ready in case market turns volatile.
Nasdaq 5000 Is Meaningless
Stay focused on price and remember that the market's riding a trend.
S&P Loses Important Support
The upward move that began in mid-October has become, at best, a sideways move.
